Skip to content Skip to footer
Viewpoints_Matt Killeen

Matt Killeen, CSO at Renovacor Shares Insights on Pipeline Expansion through its AAV Gene Therapy Program

Shots: Matt spoke about the new research program for multiple genetic segments of arrhythmogenic cardiomyopathy He also highlighted Renovacor’s research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) The interview shows Renovacor’s pipeline expansion to develop transformative therapies in genetically-driven cardiovascular diseases Smriti: Please give readers a brief insight…

Read more

ThoughtSpot_Senior Editor

How Pharma 4.0 Influences Cell and Gene Therapy

Pharma 4.0 foresees a manufacturing environment that is mostly automated and barely depends on human labor. Production systems would be interconnected with each other, as well as with supply chain management systems and quality assessment systems, all orchestrated by machine-learning-driven AI control systems. As such, smart factories promise higher productivity, better quality, and enhanced agility.…

Read more